These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 2698051)

  • 1. [The endothelium and antithrombotic substances].
    Eber B
    Acta Med Austriaca; 1989; 16(5):102-4. PubMed ID: 2698051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hirudin: clinical potential of a thrombin inhibitor.
    Johnson PH
    Annu Rev Med; 1994; 45():165-77. PubMed ID: 8198374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The importance of thrombin and its inhibition in unstable angina. Nonfractionated heparin, hirudin and defractionated heparins].
    López-Sendón J; López de Sá E; Rubio Sanz R; Delcán Domínguez JL
    Rev Esp Cardiol; 1999; 52 Suppl 1():76-89. PubMed ID: 10364817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition.
    Freund M; Mantz F; Nicolini P; Gachet C; Mulvihill J; Meyer L; Beretz A; Cazenave JP
    Thromb Haemost; 1993 May; 69(5):515-21. PubMed ID: 8322274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on thrombin-induced endothelium-dependent vascular effects.
    Glusa E; Markwardt F
    Biomed Biochim Acta; 1988; 47(7):623-30. PubMed ID: 3202849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A rationale for targeting antithrombotic therapy at the vessel wall: improved antithrombotic effect and decreased risk of bleeding.
    Buchanan MR; Brister SJ
    Wien Klin Wochenschr; 1999 Feb; 111(3):81-9. PubMed ID: 10093889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. II. Adjunctive therapy with r-hirudin.
    Rote WE; Mu DX; Bates ER; Nedelman MA; Lucchesi BR
    J Cardiovasc Pharmacol; 1994 Feb; 23(2):203-11. PubMed ID: 7511748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
    Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
    Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation.
    Harker LA; Hanson SR; Kelly AB
    Thromb Haemost; 1997 Jul; 78(1):736-41. PubMed ID: 9198248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New aspects of blood coagulation inhibitory therapy within the scope of percutaneous transluminal coronary angioplasty (PTCA)].
    Schächinger V; Zeiher AM
    Z Kardiol; 1995 Sep; 84(9):651-67. PubMed ID: 8525667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelial cells stimulated with tumor necrosis factor-alpha express varying amounts of tissue factor resulting in inhomogenous fibrin deposition in a native blood flow system. Effects of thrombin inhibitors.
    Kirchhofer D; Tschopp TB; Hadváry P; Baumgartner HR
    J Clin Invest; 1994 May; 93(5):2073-83. PubMed ID: 8182139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The endothelium, platelets, and coronary vasospasm.
    Hoak JC
    Adv Intern Med; 1989; 34():353-75. PubMed ID: 2644764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The direct thrombin inhibitor hirudin.
    Greinacher A; Warkentin TE
    Thromb Haemost; 2008 May; 99(5):819-29. PubMed ID: 18449411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The comeback of hirudin as an antithrombotic agent.
    Markwardt F
    Semin Thromb Hemost; 1991 Apr; 17(2):79-82. PubMed ID: 1771415
    [No Abstract]   [Full Text] [Related]  

  • 15. Development of hirudin as an antithrombotic agent.
    Markwardt F
    Semin Thromb Hemost; 1989 Jul; 15(3):269-82. PubMed ID: 2688099
    [No Abstract]   [Full Text] [Related]  

  • 16. Thrombin inhibition and intracoronary thrombus formation: effect of polyethylene glycol-coupled hirudin in the stenosed, locally injured canine coronary artery.
    Rübsamen K; Kirchengast M
    Coron Artery Dis; 1998; 9(1):35-42. PubMed ID: 9589189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-thrombotic effects of CX-397, a recombinant hirudin analog, in a canine model of coronary artery thrombosis.
    Ohyama T; Hori T; Moriike M; Asano T; Hayashi H; Iwade K; Hosoda S
    Thromb Haemost; 1998 Feb; 79(2):423-30. PubMed ID: 9493602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antithrombin therapy in acute coronary syndromes].
    Maseri A; Andreotti F; Biasucci LM; Rebuzzi AG
    Cardiologia; 1994 Dec; 39(12 Suppl 1):7-13. PubMed ID: 7634317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
    Hérault JP; Bernat A; Gaich C; Herbert M
    Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Inactivated factor VII exercises a powerful antithrombotic activity in an experimental model of recurrent arterial thrombosis].
    Ragni M; Golino P; Cirillo P; Pascucci I; Scognamiglio A; Ravera A; Esposito N; Battaglia C; Guarino A; Chiariello M
    Cardiologia; 1996 Jan; 41(1):51-8. PubMed ID: 8697470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.